In a bid to strengthen its immuno-oncology portfolio, Boehringer Ingelheim has entered into an agreement to acquire Nerio Therapeutics in a deal worth up to US$1.3 B. This acquisition is poised to enhance Boehringer’s capabilities in developing innovative cancer therapies, particularly through the integration of Nerio’s cutting-edge small molecule inhibitors targeting PTPN1 and PTPN2. The deal will not only bolster Boehringer’s existing pipeline but also provide new avenues for research and development in the field of immuno-oncology. The acquisition comes a few months after Boehringer’s strategic move to acquire T3 Pharmaceuticals, a bacterial cancer therapy biotech for a deal value up to US$509 M.